PL2575802T3 - Fosfaplatyny oraz ich zastosowanie w leczeniu nowotworów - Google Patents

Fosfaplatyny oraz ich zastosowanie w leczeniu nowotworów

Info

Publication number
PL2575802T3
PL2575802T3 PL11726567T PL11726567T PL2575802T3 PL 2575802 T3 PL2575802 T3 PL 2575802T3 PL 11726567 T PL11726567 T PL 11726567T PL 11726567 T PL11726567 T PL 11726567T PL 2575802 T3 PL2575802 T3 PL 2575802T3
Authority
PL
Poland
Prior art keywords
phosphaplatins
cancers
treatment
Prior art date
Application number
PL11726567T
Other languages
English (en)
Inventor
Rathindra N. Bose
Original Assignee
Ohio University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44627266&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2575802(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ohio University filed Critical Ohio University
Publication of PL2575802T3 publication Critical patent/PL2575802T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086Platinum compounds
    • C07F15/0093Platinum compounds without a metal-carbon linkage
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/245Bismuth; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL11726567T 2010-06-04 2011-06-02 Fosfaplatyny oraz ich zastosowanie w leczeniu nowotworów PL2575802T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35151410P 2010-06-04 2010-06-04

Publications (1)

Publication Number Publication Date
PL2575802T3 true PL2575802T3 (pl) 2017-04-28

Family

ID=44627266

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11726567T PL2575802T3 (pl) 2010-06-04 2011-06-02 Fosfaplatyny oraz ich zastosowanie w leczeniu nowotworów

Country Status (31)

Country Link
US (4) US9688709B2 (pl)
EP (1) EP2575802B1 (pl)
JP (1) JP5860872B2 (pl)
KR (1) KR101775410B1 (pl)
CN (6) CN108409795B (pl)
AP (1) AP3480A (pl)
AU (1) AU2011261381B2 (pl)
BR (1) BR112012030927B1 (pl)
CA (1) CA2800898C (pl)
CL (1) CL2012003416A1 (pl)
CO (1) CO6640302A2 (pl)
CY (1) CY1118466T1 (pl)
DK (1) DK2575802T3 (pl)
EA (1) EA021526B1 (pl)
ES (1) ES2606855T3 (pl)
HR (1) HRP20170225T1 (pl)
HU (1) HUE030249T2 (pl)
IL (1) IL223405B (pl)
LT (1) LT2575802T (pl)
MX (1) MX2012014174A (pl)
MY (1) MY162902A (pl)
NZ (1) NZ603952A (pl)
PH (1) PH12012502394A1 (pl)
PL (1) PL2575802T3 (pl)
PT (1) PT2575802T (pl)
RS (1) RS55714B1 (pl)
SG (1) SG185722A1 (pl)
SI (1) SI2575802T1 (pl)
SM (2) SMT201700056T1 (pl)
WO (1) WO2011153365A1 (pl)
ZA (1) ZA201209007B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2575802T3 (pl) 2010-06-04 2017-04-28 Ohio University Fosfaplatyny oraz ich zastosowanie w leczeniu nowotworów
EP2663301A1 (en) * 2011-01-12 2013-11-20 Ohio University Phosphaplatins having anti-angiogenic, anti-metastatic, and pro-apoptotic properties and uses thereof
WO2013052839A1 (en) * 2011-10-05 2013-04-11 Bose Rathindra N Efficient processes for large scale preparation of phosphaplatins antitumor agents
EP2763537B1 (en) * 2011-10-05 2018-01-10 Rathindra N. Bose Efficient processes for large scale preparation of phosphaplatins antitumor agents
ES2751668T3 (es) * 2012-05-24 2020-04-01 Phosplatin Therapeutics Llc Método de purificación para compuestos de fosfaplatino
EP2958568B1 (en) * 2013-02-22 2020-03-04 University Of Houston Phosphaplatins as neuroprotective agents
US20150231151A1 (en) * 2014-02-19 2015-08-20 University Of Houston System Compositions and methods for the treatment of neurodegenerative diseases
EA039525B1 (ru) * 2016-04-06 2022-02-07 Фосплатин Терапьютикс Инк. Фосфаплатиновые жидкие составы
JP7023968B2 (ja) * 2017-01-06 2022-02-22 フォスプラティン・セラピューティクス・インコーポレーテッド 骨がんまたは血液がんの治療のための治療薬としてのホスファプラチン化合物
AU2018327339B2 (en) * 2017-09-08 2023-10-12 Promontory Therapeutics Inc. Phosphaplatin compounds as immuno-modulatory agents and therapeutic uses thereof
JP2023547835A (ja) * 2020-10-20 2023-11-14 プロモントリー・セラピューティクス・インコーポレイテッド 高解糖性腫瘍細胞を選択的に標的化する治療剤としてのホスファプラチン化合物及びその方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4291027A (en) 1979-03-07 1981-09-22 Engelhard Minerals & Chemicals Corp. Method for treating tumors with ethylenediamine platinum (II) and 1,2-diaminocyclohexane-platinum (II) pyrophosphate complexes
US4234500A (en) 1979-03-07 1980-11-18 Engelhard Minerals & Chemicals Corporation Ethylenediamine platinum(II) and 1,2-diamino-cyclohexane platinum(II) pyrophosphate complexes
CA2017739A1 (en) 1989-07-18 1991-01-18 Engelhard Corporation Cis-diamineplatinum complexes with methanediphosphonate and substituted methanediphosphonate ligands as antitumor agents
AUPR330201A0 (en) 2001-02-23 2001-03-22 University Of Sydney, The Metal complexes and therapeutic uses thereof
DE10314780A1 (de) 2003-03-19 2004-09-30 Ktb Tumorforschungsgesellschaft Mbh Proteinbindende Derivate von Platinkomplexen mit Cyclobutan-1,1-dicarboxylatliganden
US20070160656A1 (en) 2003-05-02 2007-07-12 Dziewiszek Krzysztof J Lipid platinum complexes and methods of use thereof
WO2005000858A2 (en) 2003-06-27 2005-01-06 Akira Odani Bisphosphonate complexes
JPWO2009008345A1 (ja) 2007-07-06 2010-09-09 久雄 浴本 金属錯体化合物、これを有効成分とする癌治療剤組成物および該金属錯体化合物用の中間体
SI2173337T1 (sl) 2007-08-06 2014-10-30 Ohio University Fosfaplatini in njihova uporaba pri zdravljenju vrst raka, odpornih proti cisplatinu in karboplatinu
JP5553275B2 (ja) 2010-03-31 2014-07-16 国立大学法人金沢大学 金属錯体およびこれを有効成分として含有する抗がん剤
PL2575802T3 (pl) 2010-06-04 2017-04-28 Ohio University Fosfaplatyny oraz ich zastosowanie w leczeniu nowotworów
EP2663301A1 (en) * 2011-01-12 2013-11-20 Ohio University Phosphaplatins having anti-angiogenic, anti-metastatic, and pro-apoptotic properties and uses thereof
EP2763537B1 (en) * 2011-10-05 2018-01-10 Rathindra N. Bose Efficient processes for large scale preparation of phosphaplatins antitumor agents

Also Published As

Publication number Publication date
KR101775410B1 (ko) 2017-09-06
AP2012006594A0 (en) 2012-12-31
CN108409795A (zh) 2018-08-17
US20130064902A1 (en) 2013-03-14
JP2013529219A (ja) 2013-07-18
CN108392490A (zh) 2018-08-14
EP2575802B1 (en) 2016-11-16
US9688709B2 (en) 2017-06-27
CO6640302A2 (es) 2013-03-22
DK2575802T3 (en) 2017-01-09
US20190315789A1 (en) 2019-10-17
US10759820B2 (en) 2020-09-01
CN108409795B (zh) 2024-09-27
MX2012014174A (es) 2013-07-03
PT2575802T (pt) 2016-12-27
EP2575802A1 (en) 2013-04-10
BR112012030927A2 (pt) 2017-12-05
LT2575802T (lt) 2016-12-27
NZ603952A (en) 2014-07-25
SMT201700056T1 (it) 2017-03-08
HRP20170225T1 (hr) 2017-04-07
IL223405B (en) 2018-11-29
CY1118466T1 (el) 2017-07-12
EA201270812A1 (ru) 2013-05-30
AU2011261381A1 (en) 2013-01-10
AU2011261381B2 (en) 2015-04-02
EA021526B1 (ru) 2015-07-30
US20170327521A1 (en) 2017-11-16
US10385083B2 (en) 2019-08-20
PH12012502394A1 (en) 2013-02-04
KR20130095244A (ko) 2013-08-27
CA2800898C (en) 2018-12-04
CN108186651A (zh) 2018-06-22
CA2800898A1 (en) 2011-12-08
WO2011153365A1 (en) 2011-12-08
US20170327522A1 (en) 2017-11-16
MY162902A (en) 2017-07-31
SI2575802T1 (sl) 2017-03-31
US10364264B2 (en) 2019-07-30
CN108210516A (zh) 2018-06-29
AP3480A (en) 2015-12-31
ES2606855T3 (es) 2017-03-28
BR112012030927B1 (pt) 2021-09-21
CL2012003416A1 (es) 2013-09-06
SG185722A1 (en) 2013-01-30
JP5860872B2 (ja) 2016-02-16
CN103037859A (zh) 2013-04-10
CN108299508A (zh) 2018-07-20
ZA201209007B (en) 2013-08-28
SMT201700056B (it) 2017-03-08
RS55714B1 (sr) 2017-07-31
HUE030249T2 (en) 2017-04-28

Similar Documents

Publication Publication Date Title
IL276362A (en) Cancer treatment methods
IL248530A0 (en) Biomarkers and treatment methods
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
SG10201508495VA (en) Combination treatment of cancer
AP3480A (en) Phosphaplatins and their use for treatment of cancers
EP2539005A4 (en) ORAL PIECE AND METHODS OF USING THE SAME
IL222227A0 (en) Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
ZA201208821B (en) Methods of treatment of pancreatic cancer
ZA201300218B (en) Treatment of blood cancer
ZA201304280B (en) Treatment of jak2-mediated conditions
HRP20171352T1 (hr) Wnt-antagonisti i postupci liječenja
EP2574172A4 (en) MATERIALS AND METHOD FOR TREATING INFLAMMATION
ZA201304225B (en) Methods of treating cancer
IL256026B (en) Treatment methods
EP2640390A4 (en) METHODS OF TREATING CANCER
GB201011411D0 (en) Therapeutic compounds and their use
GB201412831D0 (en) Detection and treatment of breast cancer
GB201718726D0 (en) Phytocannabinoids in the treatment of cancer
GB201017354D0 (en) Treatment of cancer
GB201017356D0 (en) Combination treatment of cancer
GB201002499D0 (en) Treatment of tumours
HUP1000688A2 (en) Use of trifluoro-phthalimides in the treatment of cancer
ZA201301175B (en) Biomarkers and methods of treatment
GB201009194D0 (en) Treatment of pain
GB201010945D0 (en) Devices and methods for monitoring and/or treatment of tumours